Johnson & Johnson (NYSE: JNJ) has quietly emerged as a compelling turnaround story with its stock price rallying sharply in ...

In a report released today, Joanne Wuensch from Citi reiterated a Buy rating on Johnson & Johnson (JNJ – Research Report). The ...

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Antiphospholipid Syndrome.

Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase II for Soft Tissue Sarcoma.

Both these factors can be tied in part to J&J’s strong presence in the consumer sector – but behind household name products is a ... s long and varied history. Johnson & Johnson was founded ...

Johnson & Johnson currently has a 3.0% dividend yield. The outlook for the Pharmaceuticals sub-industry is positive as the world returns to normalcy and demand for electives and improved medical ...

We recently compiled a list of the 10 Best Magic Formula Stocks For The Rest Of 2024. In this article, we are going to take a ...

Johnson & Johnson (JNJ) closed the most recent trading day at $166.61, moving +1.36% from the previous trading session. This move outpaced the S&P 500's daily gain of 1.16%. At the same time, the Dow ...

The Living Well Pharmacy has adhered to Georgia legal requirements for doing so: it only sells to customers who are on the state’s medical cannabis registry.

In the latest trading session, Johnson & Johnson ... maker of health care products have appreciated by 3.82% over the course of the past month, underperforming the Medical sector's gain of ...

Johnson & Johnson refused to add warning labels to its products. The company prioritized sales over consumer safety. By filing a J&J ovarian cancer lawsuit, women across the country may now be able to ...

and Janssen’s products were less addictive than other opioids,” the city’s lawyers wrote. Johnson & Johnson produced two opioid medications cited in the complaint: Duragesic, which was a ...